相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer
Aikun Fu et al.
CELL (2022)
Next-generation cancer organoids
Bauer L. LeSavage et al.
NATURE MATERIALS (2022)
Clinical relevance of tumour-associated macrophages
Mikael J. Pittet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
Xiangliang Yuan et al.
CANCER DISCOVERY (2022)
Current and Developing Liquid Biopsy Techniques for Breast Cancer
Hsing-Ju Wu et al.
CANCERS (2022)
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
Celine M. Laumont et al.
NATURE REVIEWS CANCER (2022)
MAPK signalling-induced phosphorylation and subcellular translocation of PDHE1 alpha promotes tumour immune evasion
Yajuan Zhang et al.
NATURE METABOLISM (2022)
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Marilyne Labrie et al.
NATURE REVIEWS CANCER (2022)
Malic enzyme 2 maintains protein stability of mutant p53 through 2-hydroxyglutarate
Mengjia Zhao et al.
NATURE METABOLISM (2022)
Exploiting senescence for the treatment of cancer
Liqin Wang et al.
NATURE REVIEWS CANCER (2022)
Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma
Phuong H. D. Nguyen et al.
NATURE COMMUNICATIONS (2021)
Intratumoral heterogeneity in cancer progression and response to immunotherapy
Ilio Vitale et al.
NATURE MEDICINE (2021)
Broadening horizons: the role of ferroptosis in cancer
Xin Chen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis
Fausto Petrelli et al.
IMMUNOTHERAPY (2021)
Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance
Elina A. Pietilae et al.
NATURE COMMUNICATIONS (2021)
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inibitor Response
Meagan Montesion et al.
CANCER DISCOVERY (2021)
A review of cancer immunotherapy toxicity
Lucy Boyce Kennedy et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates
Jermaine Goveia et al.
CANCER CELL (2020)
Integrin Subtypes and Nanoscale Ligand Presentation Influence Drug Sensitivity in Cancer Cells
Jennifer L. Young et al.
NANO LETTERS (2020)
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
Maria Esperanza Rodriguez-Ruiz et al.
NATURE IMMUNOLOGY (2020)
Intratumoral heterogeneity and clonal evolution in liver cancer
Bojan Losic et al.
NATURE COMMUNICATIONS (2020)
Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma
Tomohiro Aoki et al.
CANCER DISCOVERY (2020)
The Emerging Landscape of Immune Cell Therapies
Evan W. Weber et al.
CELL (2020)
The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano-Goroff et al.
CELL RESEARCH (2020)
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
Ashley Maynard et al.
CELL (2020)
The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene
Shuiping Liu et al.
CELL DEATH & DISEASE (2020)
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence
Emma C. Madden et al.
TRENDS IN CANCER (2020)
CD8+ T cell states in human cancer: insights from single-cell analysis
Anne M. Van der Leun et al.
NATURE REVIEWS CANCER (2020)
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
C. Allison Stewart et al.
NATURE CANCER (2020)
Neoantigen-directed immune escape in lung cancer evolution
Rachel Rosenthal et al.
NATURE (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Metabolic regulation of cell growth and proliferation
Jiajun Zhu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis
Alfredo Tartarone et al.
FUTURE ONCOLOGY (2019)
Immune evasion before tumour invasion in early lung squamous carcinogenesis
Celine Mascaux et al.
NATURE (2019)
Clinical lessons learned from the first leg of the CAR T cell journey
Robbie G. Majzner et al.
NATURE MEDICINE (2019)
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer
Kroopa Joshi et al.
NATURE MEDICINE (2019)
Developing neoantigen-targeted T cell-based treatments for solid tumors
Tori N. Yamamoto et al.
NATURE MEDICINE (2019)
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
Kathrin Renner et al.
CELL REPORTS (2019)
Cancer Neoantigens
Ton N. Schumacher et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 37, 2019 (2019)
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma (vol 175, 998.e1 , 2018)
Moshe Sade-Feldman et al.
CELL (2019)
Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11
Linnea La Fleur et al.
LUNG CANCER (2019)
Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions
Vitor H. Teixeira et al.
NATURE MEDICINE (2019)
Epigenetic therapy in immune-oncology
Peter A. Jones et al.
NATURE REVIEWS CANCER (2019)
Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications
Federica Zito Marino et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Elham Azizi et al.
CELL (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Phenotype molding of stromal cells in the lung tumor microenvironment
Diether Lambrechts et al.
NATURE MEDICINE (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
Shashi Gujar et al.
TRENDS IN IMMUNOLOGY (2018)
CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment
Clare Y. Slaney et al.
CANCER DISCOVERY (2018)
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer
Siddhartha Devarakonda et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape
Carl DeSelm et al.
MOLECULAR THERAPY (2018)
Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients
Zahra Fathi et al.
PLOS ONE (2018)
Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability
Franck Raynaud et al.
PLOS GENETICS (2018)
MicroRNA-133b/EGFR axis regulates esophageal squamous cell carcinoma metastases by suppressing anoikis resistance and anchorage-independent growth
Jin-Feng Zhu et al.
CANCER CELL INTERNATIONAL (2018)
Impact of oncogenic pathways on evasion of antitumour immune responses
Stefani Spranger et al.
NATURE REVIEWS CANCER (2018)
Integrating oncolytic viruses in combination cancer immunotherapy
Praveen K. Bommareddy et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer
Kathryn C. Arbour et al.
CLINICAL CANCER RESEARCH (2018)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Epigenetic plasticity and the hallmarks of cancer
William A. Flavahan et al.
SCIENCE (2017)
miR-363-3p inhibits tumor growth by targeting PCNA in lung adenocarcinoma
Yahong Wang et al.
ONCOTARGET (2017)
Cancer metabolism: the volatile signature of glycolysis-in vitro model in lung cancer cells
Tali Feinberg et al.
JOURNAL OF BREATH RESEARCH (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Genomic Instability in Cancer: Teetering on the Limit of Tolerance
Noemi Andor et al.
CANCER RESEARCH (2017)
Exosomes secreted from human colon cancer cells influence the adhesion of neighboring metastatic cells: Role of microRNA-210
Elisabetta Bigagli et al.
CANCER BIOLOGY & THERAPY (2016)
Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils
Yanfang Liu et al.
CANCER CELL (2016)
Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis
Jitka Fucikova et al.
CANCER RESEARCH (2016)
Metabolic Heterogeneity in Human Lung Tumors
Christopher T. Hensley et al.
CELL (2016)
The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade
T. Yamazaki et al.
CELL DEATH AND DIFFERENTIATION (2016)
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Almut Brand et al.
Cell Metabolism (2016)
Kallikrein-related peptidases (KLKs) and the hallmarks of cancer
Panagiota S. Filippou et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2016)
Classification and characterization of microsatellite instability across 18 cancer types
Ronald J. Hanse et al.
NATURE MEDICINE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
Chi Lam Au Yeung et al.
NATURE COMMUNICATIONS (2016)
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Catherine Alix-Panabieres et al.
CANCER DISCOVERY (2016)
The multifaceted roles of fatty acid synthesis in cancer
Florian Roehrig et al.
NATURE REVIEWS CANCER (2016)
Glucose metabolism provide distinct prosurvival benefits to non-small cell lung carcinomas
Rongrong Wu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Protease-activated receptors (PARs)-biology and role in cancer invasion and metastasis
Marek Z. Wojtukiewicz et al.
CANCER AND METASTASIS REVIEWS (2015)
PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer
Eduardo Bonavita et al.
CELL (2015)
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Inge C. van Gool et al.
CLINICAL CANCER RESEARCH (2015)
Lysophosphatidic acid contributes to angiogenic homeostasis
Andrius Kazlauskas
EXPERIMENTAL CELL RESEARCH (2015)
Circulating Cell-Free Tumour DNA in the Management of Cancer
Glenn Francis et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review
James Sherwood et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2015)
Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients
Carola H. Schrader et al.
MOLECULAR CANCER (2015)
Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis
Miranda Y. Fong et al.
NATURE CELL BIOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immunogenicity of somatic mutations in human gastrointestinal cancers
Eric Tran et al.
SCIENCE (2015)
MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
David Casadevall et al.
ONCOTARGET (2015)
Review of aerobic glycolysis and its key enzymes - new targets for lung cancer therapy
Xue-bing Li et al.
THORACIC CANCER (2015)
Non-redundant Functions of ATM and DNA-PKcs in Response to DNA Double-Strand Breaks
Pierre Caron et al.
CELL REPORTS (2015)
The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer
Wei-Lun Huang et al.
BIOMED RESEARCH INTERNATIONAL (2015)
The Warburg effect: a balance of flux analysis
B. Vaitheesvaran et al.
METABOLOMICS (2015)
Metabolic reprogramming during TGFβ1-induced epithelial-to-mesenchymal transition
L. Jiang et al.
ONCOGENE (2015)
Cell jamming: Collective invasion of mesenchymal tumor cells imposed by tissue confinement
Anna Haeger et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2014)
Activation of membrane-bound proteins and receptor systems: a link between tissue kallikrein and the KLK-related peptidases
Ying Dong et al.
BIOLOGICAL CHEMISTRY (2014)
Growth and survival of lung cancer cells: regulation by kallikrein-related peptidase 6 via activation of proteinase-activated receptor 2 and the epidermal growth factor receptor
Noemie Michel et al.
BIOLOGICAL CHEMISTRY (2014)
Intratumoral heterogeneity and precise personalized therapy revealed by one patient panel in hepatocellular carcinoma
Qiang Gao et al.
CANCER RESEARCH (2014)
Sphingosine 1-phosphate signalling
Karen Mendelson et al.
DEVELOPMENT (2014)
Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives
Xinghua Cheng et al.
ONCOTARGETS AND THERAPY (2014)
Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment
Miriam Renovanz et al.
FRONTIERS IN ONCOLOGY (2014)
The promise of circulating tumor cell analysis in cancer management
Joaquin Mateo et al.
GENOME BIOLOGY (2014)
Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer
Winfried H. Alsdorf et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2013)
The causes and consequences of genetic heterogeneity in cancer evolution
Rebecca A. Burrell et al.
NATURE (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer
Hua Bai et al.
PLOS ONE (2013)
Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer
Lauren J. Bayne et al.
CANCER CELL (2012)
Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia
Yuliya Pylayeva-Gupta et al.
CANCER CELL (2012)
Exosomes Mediate Stromal Mobilization of Autocrine Wnt-PCP Signaling in Breast Cancer Cell Migration
Valbona Luga et al.
CELL (2012)
Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
Jahan S. Khalili et al.
CLINICAL CANCER RESEARCH (2012)
BRIM-1,-2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAFV600E mutation
Kate Young et al.
FUTURE ONCOLOGY (2012)
Lipid metabolic pathways as lung cancer therapeutic targets: A computational study
Kojiro Yano
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2012)
Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non-Small-Cell Lung Cancer
Hua Bai et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cancer immunoediting by the innate immune system in the absence of adaptive immunity
Timothy O'Sullivan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
被撤回的出版物: Redox Modification of Cysteine Residues Regulates the Cytokine Activity of High Mobility Group Box-1 (HMGB1) (Publication with Expression of Concern. See vol. 26, 2020) (Retracted article. See vol. 26, 2020)
Huan Yang et al.
MOLECULAR MEDICINE (2012)
Oxidation of HMGB1 Causes Attenuation of Its Pro-Inflammatory Activity and Occurs during Liver Ischemia and Reperfusion
Anding Liu et al.
PLOS ONE (2012)
Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer
Robert A. Beckman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Laura Senovilla et al.
SCIENCE (2012)
Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma
Yasushi Yatabe et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
Juliann Chmielecki et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Evolution of resistance to anti-cancer therapy during general dosing schedules
Jasmine Foo et al.
JOURNAL OF THEORETICAL BIOLOGY (2010)
EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases
Katharina Schmid et al.
CLINICAL CANCER RESEARCH (2009)
Hypoxia-Induced Autophagy Is Mediated through Hypoxia-Inducible Factor Induction of BNIP3 and BNIP3L via Their BH3 Domains
Gregory Bellot et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib
Kazuya Taniguchi et al.
CANCER SCIENCE (2008)
Inhibition of Stearoyl-CoA Desaturase 1 expression in human lung adenocarcinoma cells impairs tumorigenesis
Natalia Scaglia et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2008)
Phenotype of bone metastases of non-small cell lung cancer:: Epidermal growth factor receptor expression and K-RAS mutational status
Gayane Badalian et al.
PATHOLOGY & ONCOLOGY RESEARCH (2007)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N Thatcher et al.
LANCET (2005)
分享论文
